Results 171 to 180 of about 29,271 (207)

Suspected Secondary Intraocular Lymphoma With Choroidal Involvement Following Testicular Diffuse Large B-cell Lymphoma: A Case Report. [PDF]

Cureus
Ganbold B, Purevdorj B, Nguyen QD, Ganbat D.   +3 more
europepmc   +1 more source

NLRP3 inflammasome-mediated platelet hyperreactivity in sickle cell mice is targetable by BTK inhibition. [PDF]

Biochem Biophys Res Commun
Vogel S, Kamimura S, Nguyen E, Smith M, Almeida LEF, Zerfas P, Bharti K, Combs C, de Melo MS, Quezado ZMN.   +9 more
europepmc   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source

Burger JA, Barr PM, Robak T, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146(18):2168-2176.

Blood
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ibrutinib

Canadian Journal of Health Technologies
Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal ...
  +12 more sources

Ibrutinib

Reactions Weekly, 2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous, Mark-Alexander, Schwarzbich, Mathias, Witzens-Harig   +2 more
  +6 more sources